Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT

摘要

Neuroendocrine tumors are malignant solid tumors originating from neuroendocrine cells dispersed throughout the body. Differentiated neuroendocrine tumors overexpress somatostatin receptors (SSTRs), which enable the diagnosis using radiolabeled somatostatin analogues. Internalization and retention within the tumor cell are important for peptide receptor radionuclide therapy using the same peptide. The use of the same DOTA-peptide for SSTR PET/CT using 68Ga and for peptide receptor radionuclide therapy using therapeutic radionuclides like 177Lu and 90Y offers a unique theranostic advantage.